New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
16:45 EDTSCMPS&R Foundation reports 6.3% stake in Sucampo
Given its status as a majority shareholder, representatives of S&R Technology may, from time to time, engage in discussions with the company regarding its corporate strategy and general business activities.
News For SCMP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
09:13 EDTSCMPSucampo expects approvals for AMITIZA in additional European markets in 1H15
Subscribe for More Information
09:08 EDTSCMPSucampo backs FY15 EPS 55c-65c, consensus 63c
Subscribe for More Information
07:21 EDTSCMPUBS to hold a conference
Subscribe for More Information
May 11, 2015
16:34 EDTSCMPSucampo enters into licensing agreement with Harbin Gloria Pharmaceuticals
Sucampo announced that it entered into an exclusive license, development, commercialization and supply agreement with Harbin Gloria Pharmaceuticals for AMITIZA in the People's Republic of China. Through this agreement, Sucampo has granted Gloria the rights to develop and commercialize AMITIZA in China, subject to regulatory approval of the product by the China Food and Drug Administration, or CFDA. Under the terms of the agreement, Sucampo will receive an upfront payment of $1.5M and a milestone payment from Gloria. The upfront payment will consist of $1M within 30 days of signing the agreement and $500,000 within 30 days of investigational new drug application approval in China. Sucampo will also be eligible for an additional milestone payment upon the occurrence of a regulatory or alternatively a commercial milestone event. Sucampo will be the exclusive supplier of AMITIZA to Gloria at an agreed-upon supply price. The term of this agreement is 13 years with renewal terms. Gloria will be responsible for all development activities and costs. In addition, Gloria will be responsible for all commercialization and regulatory activities in China.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use